Chronic canaliculitis is an uncommon condition secondary to an infection of the lacrimal canaliculus, frequently caused by Actinomyces israelii. It is often misdiagnosed due to its symptoms mimicking more common pathologies and regularly fails to respond to antibiotics alone. Surgical intervention is the definitive treatment. We present a case of chronic canaliculitis with an unusual presentation.
Purpose: Preserflo Microshunt surgery is a new surgical procedure in the management of glaucoma. We evaluated the effectiveness and safety of Preserflo Microshunt surgery throughout the first 6 months postoperatively, by comparing intraocular pressure (IOP), number of drop agents pre and post operatively and any registered complications. Methods: A case series of 30 patients with primary open angle glaucoma underwent Preserflo Microshunt surgery at a District General Hospital in the UK. Surgical technique included scleral application of Mitomycin C 0.4 mg/mL for 3 minutes prior to microshunt insertion. Patients had their intra ocular pressure recorded pre operatively, day 1, week 2, month 2 and after 6 months. The number of therapeutic agents in their glaucoma drops was also compared pre‐operatively and after 6 months. Results: Mean IOP was reduced form 17.4 mmHg at baseline to 8.9 mmHg at 2 months and 11.6 mmHg at 6 months. The mean number of drug agents reduced from 2.25 to 0.07, and a total of 28 out of 30 (93.3%) remained drop free at 6 months. There were three cases where patients required needling of the bleb, two subsequently required repositioning of the shunt, and an IOP spike at day one post operatively in one case. Conclusions: Early results for Preserflo Microshunt surgery show sustained reduction in IOP at 6 months, with the majority of patients requiring no glaucoma drops postoperatively. The surgery has been well tolerated by patients with less intense follow up compared to a traditional trabeculectomy and low complication rates.
Purpose To describe the clinical spectrum of patients with atypical ocular toxoplasmosis, requiring confirmatory diagnosis with PCR (due to uncommon clinical presentation or non‐response to conventional treatment). Methods All cases with confirmed positive PCR for Toxoplasma gondii seen in the Bristol Eye Hospital over the last 5 years were retrospectively reviewed for patient demographic, known systemic immunosuppression, clinical presentation, response to treatment and recurrences/complications. Results A total number of 16 patients were included. Five of which were immunocompromised. Bilateral disease was seen in three cases (18.7%). The mean age at diagnosis was 64.9, with 37.5% female and 62.5% male patients. 10 out of the 19 affected eyes (52.6%) had multifocal lesions with 9 eyes (47.4%) having an isolated lesion. Eleven patients (one bilateral) had fluorescein angiography during their follow‐up, which confirmed the presence of vasculitis in nine of those eyes (75%) with five of these having occlusive vasculitis (41.7%). Of the twelve patients treated with azithromycin as first line, only 4 (25%) showed a response to treatment. Conclusions PCR is warranted to identify cases of atypical ocular toxoplasmosis. These atypical forms were also seen in immunocompetent patients. Although azithromycin has been proved to be an alternative therapy in the treatment of ocular toxoplasmosis, we identified a lack of response to azithromycin in 75% of patients in our series of patients with atypical ocular toxoplasmosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.